Neutrophil Gelatinase Associated Lipocallin (NGAL recombinant)

Added to your cart

Neutrophil Gelatinase Associated Lipocallin (NGAL recombinant)

Cart subtotal: £0.00

View cart (0) Checkout

#SKU P722-1


Price excludes shipping costs.
To view our shipping costs click here.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

NGAL is a new early marker for acute kidney injury. Levels rise rapidly after renal injury and have been used in a variety of clinical situations including intensive care, emergency medicine, renal transplantation and procedures involving the use of i.v.contrast media and other nephrotoxic agents. Studies have indicated that this marker has the greatest potential for the prediction and monitoring of acute renal injury following cardiac surgery. This potential has now been expanded upon, with development and commercialisation of highly specific ELISA testing kits.


More information



  • Shipping Information
  • Cool Pack
  • Abbreviations
  • NGAL
  • Specification
  • >96%
  • Recommended Use
  • Research and further manufacturing
  • Storage
  • Below -15°C
  • Buffer
  • lyophilised from 0.02M NH4HCO3
  • Presentation Matrix
  • lyophilised from 0.02M NH4HCO3
  • Purity/grade
  • >96%
  • Source
  • Expressed in P. pastoris
  • Molecular weight
  • 20-21kDa
  • Uniprot No.
  • P80188

Technical Documents

Product Information (414.61KB)

Certificates Of Analysis (119.15KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands


The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.


Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.


Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox